Literature DB >> 15243079

Detection and typing of human papillomavirus by e6 nested multiplex PCR.

K Sotlar1, D Diemer, A Dethleffs, Y Hack, A Stubner, N Vollmer, S Menton, M Menton, K Dietz, D Wallwiener, R Kandolf, B Bültmann.   

Abstract

A nested multiplex PCR (NMPCR) assay that combines degenerate E6/E7 consensus primers and type-specific primers was evaluated for the detection and typing of human papillomavirus (HPV) genotypes 6/11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58, 59, 66, and 68 using HPV DNA-containing plasmids and cervical scrapes (n = 1,525). The performance of the NMPCR assay relative to that of conventional PCR with MY09-MY11 and GP5+-GP6+ primers, and nested PCR with these two primer sets (MY/GP) was evaluated in 495 cervical scrapes with corresponding histologic and cytologic findings. HPV prevalence rates determined with the NMPCR assay were 34.7% (102 of 294) in the absence of cervical intraepithelial neoplasia (CIN 0), 94.2% (113 of 120) in the presence of mild or moderate dysplasia (CIN I/II), and 97.8% (44 of 45) in the presence of severe dysplasia (CIN III). The combination of all four HPV detection methods applied in the study was taken as "gold standard": in all three morphological subgroups the NMPCR assay had significantly (P < 0.0001) higher sensitivities than the MY09-MY11 and GP5+-GP6+ assays and sensitivities comparable or equal to those of the MY/GP assay. All 18 HPV genotypes investigated were detected among the clinical samples. The ratio of high- to low-risk HPV genotypes increased from 4:1 (80 of 103) in CIN 0 to 19:1 (149 of 157) in CIN I to III. Multiple infections were detected in 47.9% (124 of 259) of the patients. In conclusion, the novel NMPCR method is a sensitive and useful tool for HPV DNA detection, especially when exact HPV genotyping and the identification of multiple HPV infections are required.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15243079      PMCID: PMC446280          DOI: 10.1128/JCM.42.7.3176-3184.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 2.  Screening. The next century.

Authors:  R M Richart
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

3.  Predictive value of human papillomavirus type for histological diagnosis of women with cervical cytological abnormalities.

Authors:  M P Burger; H Hollema; W J Pieters; W G Quint
Journal:  BMJ       Date:  1995-01-14

4.  Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy.

Authors:  S Y Chan; H Delius; A L Halpern; H U Bernard
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Persistence of type-specific human papillomavirus infection among cytologically normal women.

Authors:  A Hildesheim; M H Schiffman; P E Gravitt; A G Glass; C E Greer; T Zhang; D R Scott; B B Rush; P Lawler; M E Sherman
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

6.  Detection and typing of human papillomaviruses present in fixed and stained archival cervical smears by a consensus polymerase chain reaction and direct sequence analysis allow the identification of a broad spectrum of human papillomavirus types.

Authors:  H L Smits; L M Tieben; S P Tjong-A-Hung; M F Jebbink; R P Minnaar; C L Jansen; J ter Schegget
Journal:  J Gen Virol       Date:  1992-12       Impact factor: 3.891

7.  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance.

Authors:  J T Cox; A T Lorincz; M H Schiffman; M E Sherman; A Cullen; R J Kurman
Journal:  Am J Obstet Gynecol       Date:  1995-03       Impact factor: 8.661

8.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

9.  Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes.

Authors:  M V Jacobs; A M de Roda Husman; A J van den Brule; P J Snijders; C J Meijer; J M Walboomers
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

10.  Human papillomavirus testing in primary cervical screening.

Authors:  J Cuzick; A Szarewski; G Terry; L Ho; A Hanby; P Maddox; M Anderson; G Kocjan; S T Steele; J Guillebaud
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

View more
  102 in total

1.  mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Authors:  Alfredo A Molinolo; Christina Marsh; Mohamed El Dinali; Nitin Gangane; Kaitlin Jennison; Stephen Hewitt; Vyomesh Patel; Tanguy Y Seiwert; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2012-03-12       Impact factor: 12.531

2.  Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study.

Authors:  Olcay Cem Bulut; Katja Lindel; Henrik Hauswald; Regine Brandt; Frederick Klauschen; Janina Wolf; Thomas Wolf; Peter K Plinkert; Christian Simon; Wilko Weichert; Albrecht Stenzinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-29       Impact factor: 2.503

3.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

4.  Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.

Authors:  Rosemarie Krupar; Katharina Robold; Doris Gaag; Gerrit Spanier; Marina Kreutz; Kathrin Renner; Claus Hellerbrand; Ferdinand Hofstaedter; Anja K Bosserhoff
Journal:  Virchows Arch       Date:  2014-07-16       Impact factor: 4.064

5.  Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing.

Authors:  Xinyi Cindy Zhang; Chang Xu; Ryan M Mitchell; Bo Zhang; Derek Zhao; Yao Li; Xin Huang; Wenhong Fan; Hongwei Wang; Luisa Angelica Lerma; Melissa P Upton; Ashley Hay; Eduardo Méndez; Lue Ping Zhao
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

6.  Human papillomavirus DNA detection in menstrual blood from patients with cervical intraepithelial neoplasia and condyloma acuminatum.

Authors:  Sze Chuen Cesar Wong; Thomas Chi Chuen Au; Sammy Chung Sum Chan; Charles Ming Lok Chan; Money Yan Yee Lam; Benny Chung Ying Zee; Wei Mei Pong; Anthony Tak Cheung Chan
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

7.  Gene chip technology used in the detection of HPV infection in esophageal cancer of Kazakh Chinese in Xinjiang Province.

Authors:  Wei-Gang Chen; Chun-Mei Yang; Li-Hong Xu; Ning Zhang; Xiao-Yan Liu; Yun-Gui Ma; Xiao-Ling Huo; Yu-Sheng Han; De-An Tian; Yong Zheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

8.  Prevalence and Risk Factors for Genital Human Papillomavirus Infections Among Women in Southwest Nigeria.

Authors:  Y T Nejo; D O Olaleye; G N Odaibo
Journal:  Arch Basic Appl Med       Date:  2018-05-04

9.  Ultrasensitive quantitation of human papillomavirus type 16 E6 oncogene sequences by nested real time PCR.

Authors:  Socorro Hernández-Arteaga; Rubén López-Revilla
Journal:  Infect Agent Cancer       Date:  2010-05-14       Impact factor: 2.965

10.  Perinatal transmission of human papilomavirus DNA.

Authors:  Renato L Rombaldi; Eduardo P Serafini; Jovana Mandelli; Edineia Zimmermann; Kamille P Losquiavo
Journal:  Virol J       Date:  2009-06-21       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.